Related Experiment Video

Updated: Jul 10, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Polymorphisms of the uridine-diphosphoglucuronosyltransferase 1A1 gene and coronary artery disease

Chia-Jung Hsieh1, Meng-Jung Chen, Yung-Liang Liao

  • 1Chung-Hwa University of Medical Technology, 89, Wen-Hwa 1st Street, Tainan, Taiwan.

Cellular & Molecular Biology Letters
|October 24, 2007
PubMed

Insights

Higher blood bilirubin levels correlate with lower coronary artery disease (CAD) risk. This study investigated the UGT1A1 gene variant

Area of Science:

  • Biochemistry and Molecular Biology
  • Cardiovascular Disease Research
  • Human Genetics

Background:

  • Bilirubin, a blood antioxidant, is linked to protection against atherosclerosis and coronary artery disease (CAD).
  • The enzyme uridine 5'-diphosphate-glucuronosyl transferase 1A1 (UGT1A1) conjugates bilirubin.
  • The relationship between UGT1A1 gene variations and CAD incidence has not been previously explored.

Purpose of the Study:

  • To investigate the influence of UGT1A1 gene variants on the incidence of coronary artery disease (CAD).
  • To analyze the correlation between bilirubin levels, UGT1A1 gene polymorphisms, and CAD.

Main Methods:

  • Collected blood samples from 135 participants (61 with CAD, 74 controls).
  • Assayed bilirubin levels in all participants.
  • Utilized polymerase chain reaction and UGT1A1 gene sequencing to identify polymorphisms.

Main Results:

  • Control group participants exhibited significantly higher bilirubin levels compared to the CAD group.
  • In CAD patients, UGT1A1 variants showed higher bilirubin concentrations than the wild type.
  • No significant difference in UGT1A1 gene polymorphism was observed between CAD patients and controls.

Conclusions:

  • Elevated bilirubin levels are associated with a reduced incidence of coronary artery disease.
  • While UGT1A1 variants affect bilirubin concentration, they do not appear to be a significant independent risk factor for CAD in this cohort.
  • Further research is needed to fully elucidate the complex interplay between bilirubin metabolism, UGT1A1 genetics, and cardiovascular health.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...